These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
85 related articles for article (PubMed ID: 19027811)
1. Valuable data surrounding the priming and boosting abilities of various vaccine technologies. Toback S; Ambrose C Vaccine; 2009 Jan; 27(3):349. PubMed ID: 19027811 [No Abstract] [Full Text] [Related]
4. Comparative efficacy of influenza vaccines. Narayan KM; del Rio C N Engl J Med; 2010 Jan; 362(2):179-80; author reply 180-1. PubMed ID: 20071712 [No Abstract] [Full Text] [Related]
5. [Reactogenicity and safety of inactivated chromatographic influenza vaccine in a contingent of immune donors being revaccinated]. Tentser PS; Bundzen NG Tr Inst Im Pastera; 1979; 52():43-50. PubMed ID: 550546 [No Abstract] [Full Text] [Related]
6. Efficacy of live attenuated influenza vaccine in children: A meta-analysis of nine randomized clinical trials. Rhorer J; Ambrose CS; Dickinson S; Hamilton H; Oleka NA; Malinoski FJ; Wittes J Vaccine; 2009 Feb; 27(7):1101-10. PubMed ID: 19095024 [TBL] [Abstract][Full Text] [Related]
7. MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination. Vesikari T; Groth N; Karvonen A; Borkowski A; Pellegrini M Vaccine; 2009 Oct; 27(45):6291-5. PubMed ID: 19840662 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Bracco Neto H; Farhat CK; Tregnaghi MW; Madhi SA; Razmpour A; Palladino G; Small MG; Gruber WC; Forrest BD; Pediatr Infect Dis J; 2009 May; 28(5):365-71. PubMed ID: 19395948 [TBL] [Abstract][Full Text] [Related]
12. Benefits of increasing the dose of influenza vaccine in residents of long-term care facilities: a randomized placebo-controlled trial. Cools HJ; Gussekloo J; Remmerswaal JE; Remarque EJ; Kroes AC J Med Virol; 2009 May; 81(5):908-14. PubMed ID: 19319953 [TBL] [Abstract][Full Text] [Related]
13. Development of a live-attenuated influenza B DeltaNS1 intranasal vaccine candidate. Wressnigg N; Voss D; Wolff T; Romanova J; Ruthsatz T; Mayerhofer I; Reiter M; Nakowitsch S; Humer J; Morokutti A; Muster T; Egorov A; Kittel C Vaccine; 2009 May; 27(21):2851-7. PubMed ID: 19366569 [TBL] [Abstract][Full Text] [Related]
15. Cross-reactive antibodies in middle-aged and elderly volunteers after MF59-adjuvanted subunit trivalent influenza vaccine against B viruses of the B/Victoria or B/Yamagata lineages. Camilloni B; Neri M; Lepri E; Iorio AM Vaccine; 2009 Jun; 27(31):4099-103. PubMed ID: 19410623 [TBL] [Abstract][Full Text] [Related]
16. [Which influenza vaccination is the best - with whole virus, split vaccine or subunit vaccines?]. Klenk HD; Stickl H Med Welt; 1981 Jun; 32(25):1008-9. PubMed ID: 7278577 [No Abstract] [Full Text] [Related]
17. Influenza DNA vaccine: an update. Chen Z Chin Med J (Engl); 2004 Jan; 117(1):125-32. PubMed ID: 14733788 [No Abstract] [Full Text] [Related]